Get the Stockscreener App
27.98
1.71%
0.47
After Hours:
27.98
Pharvaris Nv stock is traded at $27.98, with a volume of 248.42K.
It is up +1.71% in the last 24 hours and up +3.36% over the past month.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
See More
Previous Close:
$27.51
Open:
$27.44
24h Volume:
248.42K
Relative Volume:
0.77
Market Cap:
$1.82B
Revenue:
-
Net Income/Loss:
$-143.59M
P/E Ratio:
-9.9093
EPS:
-2.8236
Net Cash Flow:
$-119.47M
1W Performance:
+9.08%
1M Performance:
+3.36%
6M Performance:
+21.02%
1Y Performance:
+43.19%
1-Day Range:
$27.42
$28.50
1-Week Range:
$24.51
$28.50
52-Week Range:
$11.51
$29.80
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
27.98 | 1.79B | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.35 | 117.00B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 78.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
827.02 | 50.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
370.00 | 48.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.81 | 37.81B | 4.98B | 69.59M | 525.67M | 0.5197 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Initiated | H.C. Wainwright | Buy |
| Oct-09-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-11-25 | Initiated | Guggenheim | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-25-23 | Initiated | Wedbush | Outperform |
| Aug-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-05-22 | Initiated | Bryan Garnier | Buy |
| Sep-13-22 | Resumed | JMP Securities | Mkt Outperform |
| Aug-23-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-22-22 | Downgrade | BofA Securities | Neutral → Underperform |
| May-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Mar-02-21 | Initiated | BofA Securities | Neutral |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
View All
Pharvaris Nv Stock (PHVS) Latest News
Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Surprises Report: Can Pharvaris NV stock outperform in a bear marketPrice Action & Expert-Curated Trade Recommendations - baoquankhu1.vn
Layoff Watch: Is Box Inc. a speculative investmentWeekly Market Outlook & Short-Term High Return Ideas - baoquankhu1.vn
Insider Buy: How correlated is Pharvaris NV to the S P500July 2025 Final Week & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Assessing Pharvaris (PHVS) Valuation After Recent Share Price Volatility And DCF Upside Gap - Yahoo Finance
Technical Reactions to PHVS Trends in Macro Strategies - Stock Traders Daily
Pharvaris Sets 2026 Roadmap as Deucrictibant Advances Toward NDA Filing and Phase 3 Readouts - TipRanks
Pharvaris N.V. (PHVS) Stock Analysis: A Promising 83% Upside Potential Amid Biotech Advancements - DirectorsTalk Interviews
Why Pharvaris N.V. stock attracts high net worth investorsMarket Rally & Reliable Price Breakout Signals - Улправда
Why Pharvaris N.V. stock remains a top recommendationOil Prices & Real-Time Market Sentiment Reports - ulpravda.ru
Will Pharvaris N.V. (9EN) stock split increase liquidity2025 Year in Review & Capital Efficient Trade Techniques - Улправда
Street Watch: Why Pharvaris N.V. stock remains a top recommendationDay Trade & Daily Entry Point Trade Alerts - Улправда
How Pharvaris N.V. (9EN) stock reacts to fiscal policiesJuly 2025 PreEarnings & Low Volatility Stock Suggestions - Улправда
How Pharvaris N.V. stock responds to policy changes2025 Market Outlook & Real-Time Volume Trigger Notifications - Улправда
Pharvaris (NASDAQ:PHVS) Shares Up 9.1%Still a Buy? - MarketBeat
Pharvaris (NASDAQ:PHVS) Shares Down 5.7%What's Next? - MarketBeat
What analysts say about Pharvaris NV stockInstitutional Buying Trends & Use Smart Algorithms to Pick Better Stocks - earlytimes.in
LongTerm Outlook Is Uravi Defence and Technology Limited a BuyandHold StockEarnings Volatility Patterns & Low Cost Stock Ideas - earlytimes.in
CEO Moves: Is Pharvaris NV stock trading near support levelsMarket Performance Report & High Conviction Buy Zone Alerts - moha.gov.vn
Pharvaris (NASDAQ:PHVS) Raised to “Hold” at Wall Street Zen - Defense World
Trading the Move, Not the Narrative: (PHVS) Edition - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Trading 3.8% Higher – What’s Next? - Defense World
Pharvaris N.V. (PHVS) Stock Analysis: Assessing a 66.61% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Pharvaris (NASDAQ:PHVS) Shares Up 3.8%Should You Buy? - MarketBeat
Aug Retail: How Pharvaris NV stock responds to policy changesJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - moha.gov.vn
Pharvaris N.V. (NASDAQ:PHVS) Sees Large Increase in Short Interest - MarketBeat
Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Pharvaris (NASDAQ:PHVS) Shares Down 6.9%Time to Sell? - MarketBeat
Why Pharvaris (PHVS) Is Up 13.3% After RAPIDe-3 Success And 2026 Deucrictibant Filing Plans - Sahm
Behavioral Patterns of PHVS and Institutional Flows - Stock Traders Daily
Pharvaris N.V.(NasdaqGS: PHVS) added to NASDAQ Biotechnology Index - marketscreener.com
What Does Wall Street Think About Pharvaris N.V. (PHVS)? - Insider Monkey
Sentiment Recap: Is Pharvaris NV 9EN stock at risk of policy regulationQuarterly Growth Report & Consistent Return Investment Signals - moha.gov.vn
Why analysts upgrade Pharvaris N.V. stockJuly 2025 Macro Moves & Safe Entry Trade Reports - Улправда
Is Pharvaris N.V. stock trading near support levelsWeekly Volume Report & Risk Managed Investment Signals - DonanımHaber
Aug Final Week: Why analysts upgrade Pharvaris N.V. stockExit Point & Reliable Entry Point Trade Alerts - Улправда
Is Pharvaris N.V. (9EN) stock a momentum leaderJuly 2025 Final Week & Short-Term Trading Opportunity Alerts - Улправда
How geopolitical tensions affect Pharvaris N.V. stockJuly 2025 Opening Moves & Weekly Breakout Watchlists - Улправда
Total debt per share of Pharvaris N.V. – MUN:9EN - TradingView — Track All Markets
New Highs: How Pharvaris NV stock responds to policy changesWeekly Risk Summary & Reliable Intraday Trade Plans - moha.gov.vn
Pharvaris (PHVS) Is Down 5.7% After Pivotal RAPIDe-3 Deucrictibant Data And 2026 Filing Plan - Sahm
Pharvaris (NASDAQ:PHVS) Rating Lowered to Sell at Wall Street Zen - Defense World
Pharvaris N.V. $PHVS Shares Bought by TFG Asset Management GP Ltd - MarketBeat
(PHVS) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary AngioedemaSlideshow (NASDAQ:PHVS) 2025-12-09 - Seeking Alpha
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? - AOL.com
Pharvaris’ Deucrictibant Provides Rapid Relief for HAE in Phase 3 RAPIDe-3 Trial - HCPLive
Pharvaris stock gains on HAE drug meeting late-stage study goals - MSN
GENERAL ATLANTIC, L.P.'s Pharvaris NV(PHVS) Holding History - GuruFocus
Pharvaris (PHVS): Reassessing Valuation After Strong RAPIDe-3 Phase 3 Success in Hereditary Angioedema - Sahm
Pharvaris Nv Stock (PHVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):